πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Contineum Therapeutics, Inc. Class A Common Stock

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock logo
Market Cap: Medium
Employees: Low

CRG-022

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.

Tags: B-cell Malignancies, Biotechnology, CAR T-cell Therapies, Cancer Treatment, Clinical-stage

Symbol: CRGX

Recent Price: $13.76

Industry: Biotechnology

CEO: Ms. Gina Chapman

Sector: Healthcare

Employees: 150

Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403

Phone: 650-379-6143

Leadership

  • Gina Chapman, President and Chief Executive Officer
  • Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
  • Ginna Laport, MD, Chief Medical Officer
  • Shishir Gadam, PhD, Chief Technical Officer
  • Michael Ports, PhD, Chief Scientific Officer
  • Kari Leetch, Chief People Officer
  • Halley Gilbert, JD, Chief Legal Officer
  • Bethany Rogers, SVP, Product Strategy and Commercialization
  • Faisal Shawwa, SVP, Finance
  • Tonia J. Buchholz, PhD, Head of Clinical Science
  • Kanika Chawla, PhD, Head of Process Sciences
  • Sandra Chen, Head of Clinical Quality and Risk Management
  • Michelle Gray, Head of Clinical Operations
  • Adam Haskett, Head of External Manufacturing
  • David Hoffman, JD, Head of Intellectual Property & Transactions
  • Anissa Irwin, Head of Quality Assurance and Systems
  • Brett Masterson, Head of Marketing
  • Rob McCombie, Head of CMC Regulatory
  • Frank McDonald, Head of Clinical Data Management
  • Priya Parameswaran, Head of Corporate Strategy and Business Operations
  • Shabnum Patel, PHD, Head of MSAT
  • Mary Rodley, Head of CMC Strategy and Operations
  • Abhijeet Sarvaiya, Head of Statistical Programming
  • Brian Schoelkopf, Head of FP&A
  • Christophe Suchet, Head of IT
  • Beth Vasievich, PhD, Head of Commercial Planning and Operations
  • Jun Wang, Head of Procurement
  • John Orwin, Chairman of the Board
  • Abraham Bassan, Board Director
  • Kapil Dhingra, M.B.B.S, Board Director
  • Reid Huber, PHD, Board Director
  • David Lubner, Board Director
  • Krishnan Viswanadhan, Pharm.D, Board Director
  • Jane Pritchett Henderson, Board Director

Last updated: 2024-12-31

Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. Class A Common Stock logo
Market Cap: Medium
Employees: Lowest

PIPE-791

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.

Tags: biopharmaceutical, immunology, inflammation, neuroscience, pipeline

Symbol: CTNM

Recent Price: $14.47

Industry: Biotechnology

CEO: Mr. Carmine N. Stengone MBA, MS

Sector: Healthcare

Employees: 31

Address: 10578 Science Center Drive, San Diego, CA 92121

Phone: (858) 333-5280

Leadership

  • Carmine Stengone, President and Chief Executive Officer
  • Austin Chen, PhD, Senior Vice President, Head of Research
  • Beverly Dixon, Senior Director, Quality Assurance
  • Kristina Haeckl, Sr. Vice President, Regulatory Affairs
  • Daniel Lorrain, PhD, Chief Scientific Officer
  • John Healy, General Counsel & Corporate Secretary
  • Jon Seiders, PhD, Vice President, CMC
  • Jules Lee, Senior Director, Clinical Operations
  • Julie Iwashita, Vice President, Clinical Operations
  • Karin Stebbins, Vice President, Toxicology
  • Michael Mayberry, Vice President, Finance
  • Mike Poon, PhD, Vice President, Biology
  • Peter Slover, Chief Financial Officer
  • Stephen Huhn, MD, Chief Medical Officer & Senior Vice President, Clinical Development
  • Tara Vargas, Senior Director, Project Management
  • Thomas O. Schrader, PhD, Senior Director, Chemistry
  • Varsha Dourado, Vice President, Business Development

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

TELOMIR-1

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on developing and commercializing therapies for age-related inflammatory conditions and post-chemotherapy recovery.

Tags: TELOMIR-1, inflammatory conditions, pharmaceutical, stem cells, therapeutic treatment

Symbol: TELO

Recent Price: $4.64

Industry: Biotechnology

CEO: Mr. Erez Aminov

Sector: Healthcare

Employees: 1

Address: 855 N Wolfe Street, Baltimore, null 21205

Phone: (737)-289-0835

Last updated: 2024-12-31

Beam Therapeutics Inc.

Beam Therapeutics Inc. logo
Market Cap: High
Employees: Medium

precision genetic medicines

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.

Tags: Glycogen Storage Disease Type Ia, beta thalassemia, biotechnology, collaboration, genetic medicine, sickle cell disease

Symbol: BEAM

Recent Price: $25.28

Industry: Biotechnology

CEO: Mr. John M. Evans M.B.A.

Sector: Healthcare

Employees: 472

Address: 238 Main Street, Cambridge, MA 02142

Phone: 857 327 8775

Last updated: 2024-12-31

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

CT1812

Cognition Therapeutics is a clinical-stage biopharmaceutical company specializing in small molecule therapeutics for age-related degenerative diseases and central nervous system disorders. Its lead product, CT1812, is designed to treat Alzheimer's disease and dementia with Lewy bodies.

Tags: Alzheimer's disease, biopharmaceutical, central nervous system, retina disorders, small molecule therapeutics

Symbol: CGTX

Recent Price: $0.75

Industry: Biotechnology

CEO: Ms. Lisa Ricciardi

Sector: Healthcare

Employees: 25

Address: 2500 Westchester Avenue, Purchase, NY 10577

Phone: 412 481 2210

Leadership

  • Lisa Ricciardi, Chief Executive Officer​
  • Anthony C. Caggiano, M.D., Ph.D., Chief Medical Officer, Head of R&D
  • John Doyle, Chief Financial Officer
  • Anita Cornet, Head of Quality
  • Theresa Devins, DrPH, Vice President, Clinical Operations
  • Mary Hamby, Ph.D., Vice President, Research
  • Bobby Horn, Corporate Controller
  • Jennifer Iaci, Vice President, Development Operations
  • Steven A. Weissman, Ph.D., Vice President and Head of CMC
  • Jack A. Khattar, CEO
  • Aaron Fletcher, Ph.D.,
  • Brett P. Monia, Ph.D., CEO
  • Ellen B. Richstone,
  • Peggy Wallace,

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

PF614, PF614-MPAR, PF329

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing prescription drugs for severe pain relief and opioid overdose protection using proprietary abuse-resistant technologies.

Tags: clinical trials, opioid, overdose protection, pain relief, pharmaceutical

Symbol: ENSC

Recent Price: $8.62

Industry: Biotechnology

CEO: Dr. D. Lynn Kirkpatrick Ph.D.

Sector: Healthcare

Employees: 7

Address: 7946 Ivanhoe Avenue, La Jolla, CA 92037

Phone: 858 263 4196

Last updated: 2024-12-31

Structure Therapeutics Inc.

Structure Therapeutics Inc. logo
Market Cap: High
Employees: Low

GSBR-1290

Structure Therapeutics Inc. develops novel oral therapeutics for chronic diseases with unmet medical needs, focusing on conditions like type-2 diabetes, obesity, pulmonary, and cardiovascular diseases.

Tags: GPCR, biopharmaceutical, cardiovascular diseases, chronic diseases, obesity, oral therapeutics, pulmonary diseases, type-2 diabetes

Symbol: GPCR

Recent Price: $26.63

Industry: Biotechnology

CEO: Dr. Raymond C. Stevens Ph.D.

Sector: Healthcare

Employees: 136

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 628-229-9277

Last updated: 2024-12-31

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

INT230-6

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of cancer drugs for treating solid tumors. Their lead product, INT230-6, is undergoing Phase 2 trials for various cancers and is being tested in collaborations with major pharmaceutical companies.

Tags: biotechnology, cancer treatment, clinical trials, collaboration, solid tumors

Symbol: INTS

Recent Price: $1.82

Industry: Biotechnology

CEO: Mr. Lewis H. Bender M.A., M.B.A., M.S.

Sector: Healthcare

Employees: 5

Address: 61 Wilton Road, Westport, CT 06880

Phone: 203 221 7381

Leadership

  • Lewis H. Bender, M.S., M.A., M.B.A., Founder and CEO
  • Joseph Talamo, CPA, Chief Financial Officer
  • James M. Ahlers, Executive Vice President
  • Brian Schwartz, MD, Executive VP, Clinical Development
  • John Wesolowski, CPA, MBA, Principal Accounting Officer and Controller
  • Kimberly A. Guedes, RN, MBA, Vice President of Clinical Operations
  • Doranne Frano, Regulatory Affairs and Quality Control
  • Daniel J. Donovan, Board Member and Chief Executive Officer
  • Tom Dubin, Board Member
  • Mark A. Goldberg, MD, Board Member
  • Emer Leahy, Ph.D., Board Member

Last updated: 2024-12-31

Century Therapeutics, Inc.

Century Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

CNTY-101

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.

Tags: CAR-i NK, CAR-i T, allogeneic, biotechnology, cell therapy, hematological malignancies, iPSC, solid tumors

Symbol: IPSC

Recent Price: $1.00

Industry: Biotechnology

CEO: Mr. Brent Pfeiffenberger M.B.A., Pharm.D.

Sector: Healthcare

Employees: 152

Address: 3675 Market Street, Philadelphia, PA 19104

Phone: 267 817 5790

Last updated: 2024-12-31

Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

PLN-74809

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Their lead product candidate, PLN-74809, is currently in Phase 2a trials.

Tags: biopharmaceutical, clinical trials, fibrosis, integrin inhibitor, therapies

Symbol: PLRX

Recent Price: $12.79

Industry: Biotechnology

CEO: Dr. Bernard Coulie M.B.A., M.D., Ph.D.

Sector: Healthcare

Employees: 166

Address: 260 Littlefield Avenue, South San Francisco, CA 94080

Phone: 650 481 6770

Last updated: 2024-12-31

Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc. logo
Market Cap: Low
Employees: Medium

P-PSMA-101

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on developing innovative CAR-T therapies for patients with high unmet medical needs, including treatments for prostate cancer, multiple myeloma, and various solid tumors.

Tags: CAR-T therapy, biopharmaceutical, cancer treatment, clinical-stage, innovative therapeutics

Symbol: PSTX

Recent Price: $9.48

Industry: Biotechnology

CEO: Dr. Kristin Yarema Ph.D.

Sector: Healthcare

Employees: 337

Address: 9390 Towne Centre Drive, San Diego, CA 92121

Phone: 858 779 3100

Last updated: 2024-12-31

Regulus Therapeutics Inc.

Regulus Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

RG-012 and RGLS8429

Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.

Tags: biopharmaceutical, clinical stage, drug development, kidney disease, micro RNAs

Symbol: RGLS

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Joseph P. Hagan M.B.A.

Sector: Healthcare

Employees: 30

Address: 4224 Campus Point Court, San Diego, CA 92121

Phone: 858 202 6300

Last updated: 2024-12-31

Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

SEL-302, SEL-212

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. The company has various programs including gene therapies and biologic therapies for conditions like methylmalonic acidemia and chronic refractory gout.

Tags: autoimmune diseases, biologic therapies, biopharmaceutical, gene therapy, nanoparticle drugs

Symbol: RNAC

Recent Price: $18.76

Industry: Biotechnology

CEO: Dr. Carsten Brunn Ph.D.

Sector: Healthcare

Employees: 37

Address: 65 Grove Street, Watertown, MA 02472

Phone: 617 923 1400

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TPST-1495, TPST-1120, TREX-1

Tempest Therapeutics Inc. is a clinical-stage oncology company developing small molecule therapeutics to treat cancer, with key programs in TPST-1495 and TPST-1120, and research in TREX-1 enzyme modulation.

Tags: biotechnology, cancer treatment, clinical-stage, drug development, immune response, oncology, small molecule therapeutics

Symbol: TPST

Recent Price: $0.84

Industry: Biotechnology

CEO: Mr. Stephen R. Brady J.D., LLM

Sector: Healthcare

Employees: 17

Address: 7000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 798 8589

Last updated: 2024-12-31

PaxMedica, Inc. Common Stock

PaxMedica, Inc. Common Stock logo
Market Cap: Lowest
Employees: Lowest

PAX-101

Pax Medica, Inc., is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for treating intractable neurologic disorders. Their lead product, PAX-101, is an intravenous formulation of suramin for indications such as autism spectrum disorder and chronic fatigue syndrome.

Tags: Autism Treatment, Biopharmaceutical, Chronic Fatigue Syndrome, Drug Development, Neurologic Disorders

Symbol: PXMD

Recent Price: $0.06

Industry: Biotechnology

CEO: Mr. Howard J. Weisman

Sector: Healthcare

Employees: 6

Address: 303 South Broadway, Tarrytown, NY 10591

Phone: 914-987-2876

Last updated: 2024-12-31

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

TERN-101, TERN-201, TERN-501, TERN-601

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity, incorporating products like TERN-101, TERN-201, TERN-501, and TERN-601.

Tags: NASH, biopharmaceutical, clinical trials, obesity, pharmaceutical research

Symbol: TERN

Recent Price: $7.15

Industry: Biotechnology

CEO: Ms. Amy L. Burroughs M.B.A.

Sector: Healthcare

Employees: 66

Address: 1065 East Hillsdale Boulevard, Foster City, CA 94404

Phone: 650 525 5535

Last updated: 2024-11-08